Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

19/12/2016 ​Foundation stone ceremony for Natura Bissé’s new world headquarters in Barcelona Synchrotron Park 15/12/2016 ​The Bioregion of Catalonia in Nature 07/12/2016 Digitus II Awarded By Barcelona Synchrotron Park As Best Business Idea Of The UAB University Research Park 29/11/2016 ​The European Commission awards the “Business & Biodiversity” label to Barcelona Synchrotron Park 21/11/2016 ​Barcelona 2nd Smart City in the World 15/11/2016 Barcelona Synchrotron Park Sponsors the PRUAB Ideas Generation Program
20 21 22 23 24 25 26 27 28 29 30